Getinge B with clear long-term strategy, shares in the medtech peer comparison
29.06.2026 - 12:09:31 | ad-hoc-news.de
By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-29, 12:08.
Getinge B (SE0000202624) enters the new week with investors once again assessing its long-term strategy in the global medtech sector. The Stockholm-listed group competes with larger peers such as Siemens Healthineers and Philips in critical-care and surgical equipment.
What recent figures show
For the first quarter of 2026, Getinge reported stable development in high-margin therapy products, while earlier the company had highlighted efficiency measures and portfolio focus in critical-care and cardiopulmonary segments, according to its recent financial reports. Latest Getinge financial reports The company emphasized cash flow discipline and targeted investments in innovation as key elements of its plan.
In the broader European medtech space, peers such as Siemens Healthineers and Philips continue to work on margin improvements and cost programs, which keeps investor attention on Getinge’s ability to protect profitability while investing in growth initiatives, as highlighted by recent sector commentary from European equity analysts. Reuters overview of Getinge and medtech peers
Analyst focus on margins and growth
Analyst discussions around Getinge frequently center on operating margin trends, currency exposure and the balance between mature products and new technology platforms, according to recent consensus snapshots from European broker platforms. MarketScreener consensus data for Getinge Rating distributions show a mix of Hold and Buy recommendations, reflecting both the defensive qualities of the healthcare sector and execution risks in restructuring and innovation.
For long-term investors, topics such as recurring revenues from service contracts, installed base expansion, and exposure to hospital capital expenditure cycles in Europe and North America remain central in research commentary on the stock, particularly when compared with other S&P Europe 350 healthcare names and global medtech benchmarks.
Background and price data on Getinge B
All news, reports and historical data on the Getinge B shares can be found bundled in the dedicated topic area and in the company’s investor relations section.
How Getinge makes its money
Getinge generates revenue primarily from advanced medical equipment and associated services for operating rooms, intensive care units and sterile reprocessing departments in hospitals worldwide. A representative product line is its Maquet operating tables, which are used in surgical suites in Europe, North America and other regions.
Where the shares trade today
The Getinge B shares (SE0000202624) trade on Nasdaq Stockholm, with the latest available price data published in Swedish krona on the Stockholm exchange price pages.
Key data on the Getinge B shares
- Company: Getinge AB
- ISIN: SE0000202624
- WKN: 888506
- Ticker: GETI B
- Trading venue: Nasdaq Stockholm
- Price (as of 2026-06-28, 17:30): 229.60 SEK
- Market cap: 58.0 billion SEK (as of 2026-06-28)
- Sector / industry: Healthcare equipment and supplies
- Index membership: OMX Stockholm Benchmark
- Next earnings date: 2026-07-16
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. All data are based on sources considered reliable but cannot be guaranteed.
